Type 2 Diabetes drug metformin is the latest medicine to be recalled due to unacceptable levels of the probable human carcinogen NDMA (N-Nitrosodimethylamine).

The FDA said it found unacceptable levels of NDMA (N-Nitrosodimethylamine) in extended-release versions of the type 2 diabetes drug metformin.

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) called for new product information for hormone replacement therapy (HRT) to reflect the risk of breast cancer.